Holen Sie sich die Stockscreener-App
0.122
7.22%
-0.0095
Vorhandelsmarkt:
.12
-0.002
-1.64%
Schlusskurs vom Vortag:
$0.1315
Offen:
$0.1236
24-Stunden-Volumen:
18.23M
Relative Volume:
1.34
Marktkapitalisierung:
$1.74M
Einnahmen:
$212.10K
Nettoeinkommen (Verlust:
$-40.19M
KGV:
-0.000023
EPS:
-5313.2836
Netto-Cashflow:
$-13.92M
1W Leistung:
-9.70%
1M Leistung:
-34.44%
6M Leistung:
-99.81%
1J Leistung:
-99.92%
1-Tages-Spanne:
$0.115
$0.1249
1-Wochen-Bereich:
$0.115
$0.2077
52-Wochen-Spanne:
$0.115
$218.00
Aditxt Inc Stock (ADTX) Company Profile
Firmenname
Aditxt Inc
Sektor
Branche
Telefon
909-488-0844
Adresse
737 N. FIFTH STREET, SUITE 200, RICHMOND
Vergleichen Sie ADTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADTX
Aditxt Inc
|
0.122 | 1.74M | 212.10K | -40.19M | -13.92M | -5,313.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aditxt Inc Aktie (ADTX) Neueste Nachrichten
Aditx Therapeutics stock hits 52-week low at $0.12 - Investing.com
Aditxt (NASDAQ: ADTX) Board Considers IPO for Subsidiary PearsantaMountain View, CA – January 13, 2025 – Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”) announced today that its Board of Directors has given the green light for exploring the p - Defense World
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Aditxt explores IPO for subsidiary Pearsanta in 2025 By Investing.com - Investing.com Canada
Aditxt explores IPO for subsidiary Pearsanta in 2025 - Investing.com India
Aditxt, Inc. Plans IPO for Pearsanta in 2025 - TipRanks
Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform - Quantisnow
Aditx Therapeutics stock hits 52-week low at $0.17 By Investing.com - Investing.com Australia
Aditx Therapeutics stock hits 52-week low at $0.17 - Investing.com
Shares Of Aditxt Inc (NASDAQ: ADTX): Are They Overvalued Compared To Others? - Stocks Register
Aditxt Inc (NASDAQ: ADTX) Inclines 3.78%: This $2.72 million Stock Could Go Down -79900.0% - Stocks Register
Perspective Therapeutics Inc (AMEX: CATX) Could Fell Another -684.31% - Stocks Register
Devon Energy Corp (NYSE: DVN) Stock Forecast: Could Pass $55 In A Year - Stocks Register
No Stopping Energy Transfer LP (NYSE: ET)’s Stock Surged? - Stocks Register
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Down 45.2% in December - Defense World
ADTX stock plunges to 52-week low, touches $0.18 By Investing.com - Investing.com Nigeria
ADTX stock plunges to 52-week low, touches $0.18 - Investing.com
Aditx Therapeutics stock hits 52-week low at $0.31 By Investing.com - Investing.com Canada
Aditx Therapeutics stock hits 52-week low at $0.31 - Investing.com
Aditxt, Inc. (NASDAQ:ADTX) Sees Large Decrease in Short Interest - Defense World
Aditxt Advances ADI-100 Therapy to Human Trials - TipRanks
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials - Quantisnow
Leslies Inc (LESL) Is Worth A Look Now, Despite -69.79% Loss From High - Stocks Register
Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits - Quantisnow
Evofem Biosciences Announces Financial Results for the Third Qua - GuruFocus.com
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - Marketscreener.com
Aditxt extends merger agreement end date to January 2025 - Investing.com
Aditxt extends merger agreement end date to January 2025 By Investing.com - Investing.com UK
Appili Therapeutics Moves Forward with Aditxt Acquisition - TipRanks
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. - The Manila Times
Evofem Secures Investor Support for Proposed Merger through Voti - GuruFocus.com
Aditxt Inc. (ADTX) Quarterly 10-Q Report - Quartz
Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ADTX stock plunges to 52-week low of $0.32 amid market challenges - Investing.com Canada
Evofem Cuts Q3 Operating Loss 31%, Acquires SOLOSEC Rights Despite Sales Dip | ADTX Stock News - StockTitan
Enviri Corp (NYSE: NVRI): Blank Check On Growth? - Stocks Register
Appili Therapeutics shareholders vote in favor of Aditxt transaction - TipRanks
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 - The Manila Times
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Update - Defense World
Aditxt suspends equity financing amid acquisition strategy - Investing.com
Aditxt suspends equity financing amid acquisition strategy By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low, touches $0.42 - Investing.com India
ADTX stock plunges to 52-week low, touches $0.42 By Investing.com - Investing.com UK
Aditxt Secures Overwhelming Shareholder Approval for Appili Therapeutics Acquisition | ADTX Stock News - StockTitan
Appili Shareholders Approve Acquisition by Aditxt - TipRanks
Appili Therapeutics Announces Results of Special Meeting of Shareholders - Financial Post
Appili Therapeutics Announces Results of Special Meeting of Shareholders - GlobeNewswire Inc.
Aditxt announces Evofem secures voting agreements with investors for merger - TipRanks
Evofem Biosciences Gains Support for Aditxt Merger - TipRanks
Finanzdaten der Aditxt Inc-Aktie (ADTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aditxt Inc-Aktie (ADTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Oct 16 '24 |
Sale |
1.17 |
25,534 |
29,875 |
0 |
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):